Absorção de triagem de câncer de mama: um estudo controlado randomizado avaliando o efeito de um auxílio à decisão (DEDICACES2)
Tomada de Decisão Compartilhada para o Rastreamento do Câncer de Mama na Atenção Primária
Shared decision-making for organised breast cancer screening (OBCS) could be improved by fostering interaction and exchanges of information between women and General Practitioners (GPs), for instance by including an assistance tool in the dispatch of the invitation letter for Organised Screening for breast cancer. In 2018 the national cancer Institute funded the development of a decisional aid (DA) on the theme of whether or not to take part in breast cancer screening, specific to the French setting. It is the website lamammo-etvous.fr DEDICACES project 1.
DEDICACES 2 is a population-based trial with a cluster design. It studies humans, without modifying their usual care. The experiment assesses the effect of the lamammo-etvous.fr/ tool on the decision to take part (or not) in OBCS among women who are invited for screening.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Nantes, França, 44093
- University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria :
- General practitioners (GPs):
The following GPs will be included:
1) Practicing in one of the French départements (administrative area) covered by the study.
- Women:
The following women will be included:
- Invited to participate in OBCS by the National Health Insurance Agency (Caisse Nationale d'Assurance Maladie; CNAM) during the studied month: eligible for OBCS, therefore aged between 50 and 74 at the time of inclusion;
- On the patient list of a GP who is covered by the study at the time of inclusion;
- Covered by one of the CPAM (Caisse Primaire d'Assurance Maladie) in the participating departments.
Exclusion Criteria :
- General practitioners (GPs) :
The following GPs will be excluded:
-
Those who do not have any patients invited for OBCS in the studied month;
-
Those whose practice does not correspond to the usual activities of a GP (known as a Mode d'Exercice Particulier), or who have very few patients (who have seen fewer than 100 different patients in the year preceding the experiment);
-
Those who practice within a health centre (as it is impossible to evaluate the activity of an individual practitioner in health insurance databases);
-
Those who explicitly state that they do not want to take part in the study, in response to an initial letter of invitation. This letter will inform them that the study is being run, and will inform them of the option to refuse to participate if they so wish;
-
Those who are participating in the MyPEBS study (the only national study of OBCS at the time the present protocol was drawn up).
- Women:
The following women will not be included:
- Participants in the MyPEBS study ( the only national study of OBCS at the time the present protocol was drawn up); or,
- If their GP refuses to participate in the study; or,
- women under guardianship.
The following women will be excluded:
- Those who object to the study in accordance with regulatory procedures issued by the Data Protection Officer (DPO),
- Those who do not respond within 1 month after the questionnaire has been sent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Decisional aid for organised cancer screening
Women will receive a leaflet that presents the tool. The leaflet includes a link to access the tool, and encourages the person to consult their GP to initiate the shared decision-making process. GPs will receive a letter presenting the study that includes: a) information about shared decision-making and how to implement it; b) the letter that is sent to their patients, and c) a recommendation to implement shared decision-making with their patients. |
The leaflet will include a link to access the https://lamammo-etvous.fr DA aid tool, and will inform women about shared decision-making. The GPs of women who are sent the leaflet will also be sent a letter encouraging shared decision-making. This material will be sent 3 months after women have received their breast cancer screening invitation letter. Data related to primary and secondary objectives will be collected by questionnaire from the 2 groups. The questionnaire will be sent 2 months after participants are informed about the tool. |
|
Sem intervenção: Standard organised cancer screening
Women and their GPs will continue to carry out usual screening. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Evaluation of the effectiveness of the /lamammo-etvous.fr/ DA tool on decision-making concerning the choice of whether or not to participate in OBCS among women who are invited for screening.
Prazo: 2 months
|
Overall score on the 16-item Decisional Conflict Scale (DCS). Measured 2 months after participants are informed about the tool, in both arms. 5 response categories: 1 = strongly agree; 5 = strongly disagree. Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict]. |
2 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Evaluation of the effect of the presentation of the /lamammo-etvous.fr/ tool on the intention to participate in OBCS.
Prazo: 2 months
|
Score on a one-item (Measures of Decision) scale measuring intention to participate in OBCS. Measured 2 months after participants are informed about the tool, in both arms. Respondents check a box lying on a 15-point scale ranging from "I wish to participate in breast cancer screening" to "I do not wish to participate in breast cancer screening", with "I'm not sure" in the middle. Scores will be reclassified as follows: 1-5 (yes); 6-10 (unsure); 11-15 (no). |
2 months
|
|
Evaluation of the effect of presenting the /lamammo-etvous.fr/ DA tool on the implementation of shared decision-making.
Prazo: 2 months
|
Scores on the 9-item Shared Decision Making Questionnaire (SDM Q9). Measured 2 months after presentation of the tool, in both arms. Six response categories: 10 = completely disagree; 5 = completely agree. Scores are reported on a scale ranging from 0 (the lowest possible level of SDM) to 100 ( the highest extent of SDM). |
2 months
|
|
Evaluation of the effect of presenting the /lamammo-etvous.fr/ DA tool on women's knowledge of OBCS.
Prazo: 2 months
|
Number of correct responses to a 10-item questionnaire that tests OSBC-related knowledge. The questionnaire was developed in the context of the DEDICACES project (part 1) and is based on items included in the IPDAS (International Patient Decision Aid Standards) score. Measured 2 months after presentation of the support tool, in both arms. |
2 months
|
|
Evaluation of the effect of the presentation of the /lamammo-etvous.fr/ DA tool on women's care pathways following an invitation to participate in OBCS.
Prazo: 2 months
|
Data related to care pathways 2 months after presentation of the DA tool, in both arms: mammograms completed; appointments made to undergo mammography; appointments made to discuss screening; type of professionals contacted by participants (GP, midwife, gynaecologist, other). |
2 months
|
|
Evaluation of the effect of presenting the /lamammo-etvous.fr/ DA tool on decisional conflict in subgroups characterized by lower participation in OBCS.
Prazo: 2 months
|
Collection of socio-demographic patient data (home, work, marital status, in receipt of state aid) and health data (long-term illness, history of participation in OBCS, history of participation in colon cancer screening). Data collected 2 months after presentation of the DA tool, in both arms. |
2 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Cédric Rat, M.D. PhD., Nantes University Hospital, Faculty of medicine, General Practice Department, Nantes, France
- Investigador principal: Sandrine Hild, M.D., Nantes University Hospital, Faculty of medicine, General Practice Department, Nantes, France
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- RC20_0532
- 2024-A00987-40 (Número de outro subsídio/financiamento: National Cancer Institute)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .